1301. Vaccines and Immunosuppression @wearesrna
1301. Vaccines and Immunosuppression  @wearesrna
Uploaded February 2025 | Updated November 2026, 3 hours ago
In this episode of "Ask the Expert," Dr. Eoin Flanagan joined Dr. GG deFiebre of SRNA. Dr. Flanagan explained how immunosuppressive medications impact the immune system and the efficacy of vaccines [00:02:45]. He discussed the primary concerns and risks of vaccinating individuals on these therapies, including avoiding live vaccines and the need for additional booster doses [00:04:52]. Dr. Flanagan also talked about the recommended vaccines for those with conditions like MOG antibody disease (MOGAD) and neuromyelitis optica spectrum disorder (NMOSD), and underlined the importance of getting vaccinated to prevent severe infections [00:09:40]. He addressed common misconceptions and emphasized the role of healthcare providers in educating and supporting their patients regarding vaccinations [00:15:32].

Eoin Flanagan, MB, BCh is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He completed his medical school training at University College Dublin in Ireland in 2005. He did a medical residency in Ireland and then completed neurology residency, fellowships in neuroimmunology and a masters in clinical and translational science at Mayo Clinic (Rochester, MN). He works in the Autoimmune Neurology and Multiple Sclerosis Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. His clinical expertise and research are focused on inflammatory myelopathies and their imaging patterns, myelin oligodendrocyte glycoprotein (MOG) antibody associated disorder, neuromyelitis optica spectrum disorders, autoimmune encephalitis, paraneoplastic neurologic disorders, and multiple sclerosis. He is principal investigator on an NIH RO1 grant studying MOG antibody associated disorder.

00:00 Introduction
00:47 Understanding Immunosuppressants and Vaccines
01:28 Primary Concerns with Vaccinating Immunosuppressed Patients
02:30 Recommended Vaccines for Immunosuppressed Patients
07:11 Timing and Effectiveness of Vaccinations
08:21 Measuring Vaccine Response
09:24 Addressing Missed Doses and Safety Considerations
16:41 Public Health Implications and Patient Advocacy
17:56 Advice for Vaccine-Hesitant Patients
19:06 Healthcare Providers' Role in Vaccination
20:03 Conclusion and Final Thoughts
1301. Vaccines and Immunosuppression2024 RNDS | Community Perspectives Panel: Navigating Work, Travel, Setting Boundaries, and More2026 RNDS | TIMELY-PLEX Study2025 RNDS | Rehabilitation and recovery in rare neuroimmune disorders2026 RNDS | Getting Back to WorkThe Power Of Community: Teaser2025 RNDS | 2025 Update on the Q-cells Study1112. Social Determinants of Health in Rare Neuroimmune Disorders2026 RNDS | Sexual Dysfunction and Intimacy2024 RNDS | A Conversation: How Do I Identify a Relapse?1302. Pelvic Floor Therapy for Bladder and Bowel ManagementABCs of NMOSD 702. CAR-T in NMOSD
SRNA |

1301. Vaccines and Immunosuppression

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER